Risk factors for colorectal neoplasia in inflammatory bowel disease: A nested case-control study from Copenhagen County, Denmark and Olmsted County, Minnesota

American Journal of Gastroenterology

Volumn 102, Issue 4, 2007, Pages 829-836

  Jess, Tine ^a   Loftus Jr , Edward V ^b   Velayos, Fernando S ^c   Winther, Karen V ^a   Tremaine, William J ^b   Zinsmeister, Alan R ^b   Scott Harmsen, W ^b   Langholz, Ebbe ^a   Binder, Vibeke ^a   Munkholm, Pia ^a   Sandborn, William J ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; SALAZOSULFAPYRIDINE;

ARTICLE; BARIUM ENEMA; CANCER RISK; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL OBSERVATION; COHORT ANALYSIS; COLONOSCOPY; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROHN DISEASE; DEMOGRAPHY; DENMARK; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; ENTERITIS; FEMALE; FOLLOW UP; HEALTH SERVICE; HIGH RISK POPULATION; HUMAN; INTESTINE RESECTION; LOGISTIC REGRESSION ANALYSIS; MALE; MEDICAL RECORD; PHYSICIAN; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RADIATION EXPOSURE; RISK FACTOR; SMALL INTESTINE; SYMPTOM; ULCERATIVE COLITIS; UNITED STATES; X RAY ANALYSIS;

ADULT; CASE-CONTROL STUDIES; COLONOSCOPY; COLORECTAL NEOPLASMS; DENMARK; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; LOGISTIC MODELS; MALE; MESALAMINE; MINNESOTA; POPULATION SURVEILLANCE; PRECANCEROUS CONDITIONS; PROGNOSIS; RISK FACTORS; SULFASALAZINE;

EID: 33947668450     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01070.x     Document Type: Article

References (36)

1. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut 2001;48:526-35.
2. Jess T, Gamborg M, Matzen P, et al. Increased risk of intestinal cancer in Crohn's disease: A meta-analysis of population-based cohort studies. Am J Gastroenterol 2005;100:2724-9
3. Greenstein AJ, Sachar DB, Smith H, et al. A comparison of cancer risk in Crohn's disease and ulcerative colitis. Cancer 1981;48:2742-5.
4. Ekbom A, Helmick C, Zack M, et al. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 1990;336:357-9.
5. Jess T, Winther KV, Munkholm P, et al. Intestinal and extra-intestinal cancer in Crohn's disease: Follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther 2004;19:287-93.
6. Jess T,WintherKV,Munkholm P, et al.Mortality and causes of death in Crohn's disease: Follow-up of a population-based cohort in Copenhagen County, Denmark. Gastroenterology 2002;122:1808-14.
7. Pinczowski D, Ekbom A, Baron J, et al. Risk factors for colorectal cancer in patients with ulcerative colitis: A case-control study. Gastroenterology 1994;107:117-20.
8. Moody GA, Jayanthi V, Probert CS, et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: A retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996;8:1179-83.
9. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: A case-control study. Aliment Pharmacol Ther 2000;14:145-53.
10. Bansal P, Sonnenberg A. Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol 1996;91:44-8.
11. Lashner BA. Red blood cell folate is associated with the development of dysplasia and cancer in ulcerative colitis. J Cancer Res Clin Oncol 1993;119:549-54.
12. Pardi DS, Loftus EV Jr, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124:889-93.
13. Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134:89-95.
14. Munkholm P. Crohn's disease - occurrence, course and prognosis. An epidemiologic cohort-study. Dan Med Bull 1997;44:287-302.
15. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: Asystematic reviewand metaanalysis of observational studies. Am J Gastroenterol 2005;100:1345-53.
16. Langholz E, Munkholm P, Davidsen M, et al. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992;103:1444-51.
17. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990;323:1228-33.
18. Nuako KW, Ahlquist DA, Mahoney DW, et al. Familial predisposition for colorectal cancer in chronic ulcerative colitis: A case-control study. Gastroenterology 1998;115:1079-83.
19. Sandborn WJ, Loftus EV Jr, Ahlquist DA. Association of primary sclerosing cholangitis and colorectal cancer in patients with ulcerative colitis: Is it true and does it matter? Gastroenterology 1998;115:236-7.
20. Loftus EV Jr, Aguilar HI, Sandborn WJ, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology 1998;27:685-90.
21. Broome U, Lofberg R, Veress B, et al. Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential. Hepatology 1995;22:1404-8.
22. Heuschen UA, Hinz U, Allemeyer EH, et al. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology 2001;120:841-7.
23. Winther KV, Jess T, Langholz E, et al. Long-term risk of cancer in ulcerative colitis: A population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004;2:1088-95.
24. Jess T, Loftus EV Jr, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: A population-based study from Olmsted County, Minnesota, 1940-2001. Gastroenterology 2006;130:1039-46.
25. Langholz E. Ulcerative colitis. An epidemiological study based on a regional inception cohort, with special reference to disease course and prognosis. Dan Med Bull 1999;46:400-15.
26. Winther KV, Jess T, Langholz E, et al. Survival and cause-specific mortality in ulcerative colitis: Follow-up of a population-based cohort in Copenhagen County. Gastroenterology 2003;125:1576-82.
27. Melton LJ 3rd. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996:266-74.
28. Loftus CG, Loftus EV Jr, Sandborn WJ, et al. Update on incidence and prevalence of Crohn's disease (CD) and ulcerative colitis (UC) in Olmsted County, Minnesota. Gastroenterology 2003;124:A36[abstract].
29. Winther KV, Bruun E, Horn T, et al. Screening for dysplasia in patients with 22-40 years of ulcerative colitis in a population-based cohort from Copenhagen County. Gastroenterology 2003;124:A1435[abstract].
30. Jess T, Loftus EV Jr, Velayos FS, et al. Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: Apopulation-based study from Olmsted County, Minnesota. Inflamm Bowel Dis 2006;12:669-76.
31. Rutter M, Saunders B,Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451-9.
32. Orholm M, Binder V, Sorensen TI, et al. Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand J Gastroenterol 2000;35:1075-81.
33. Johnson GJ, Cosnes J, Mansfield JC. Review article: Smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol Ther 2005;21:921-31.
34. Ron E. Cancer risk from medical radiation. Health Phys 2003;85:47-59.
35. Velayos FS, Loftus EV Jr, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology 2006;130:1941-9
36. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: Clinical outcome in a population based cohort from Stockholm County. Gut 2004;53:849-53.